Literature DB >> 18508830

Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression.

M Molina-Molina1, A Xaubet, X Li, A Abdul-Hafez, K Friderici, K Jernigan, W Fu, Q Ding, J Pereda, A Serrano-Mollar, A Casanova, E Rodríguez-Becerra, F Morell, J Ancochea, C Picado, B D Uhal.   

Abstract

Angiotensin II is a growth factor that plays a key role in the physiopathology of idiopathic pulmonary fibrosis (IPF). A nucleotide substitution of an adenine instead of a guanine (G-6A) in the proximal promoter region of angiotensinogen (AGT), the precursor of angiotensin II, has been associated with an increased gene transcription rate. In order to investigate whether the G-6A polymorphism of the AGT gene is associated with IPF development, severity and progression, the present study utilised a case-control study design and genotyped G-6A in 219 patients with IPF and 224 control subjects. The distribution of G-6A genotypes and alleles did not significantly differ between cases and controls. The G-6A polymorphism of the AGT gene was not associated with disease severity at diagnosis. The presence of the A allele was strongly associated with increased alveolar arterial oxygen tension difference during follow-up, after controlling for the confounding factors. Higher alveolar arterial oxygen tension changes over time were observed in patients with the AA genotype (0.37+/-0.7 mmHg (0.049+/-0.093 kPa) per month) compared to GA genotype (0.12+/-1 mmHg (0.016+/-0.133 kPa) per month) and GG genotype (0.2+/-0.6 mmHg (0.027+/-0.080 kPa) per month). G-6A polymorphism of the angiotensinogen gene is associated with idiopathic pulmonary fibrosis progression but not with disease predisposition. This polymorphism could have a predictive significance in idiopathic pulmonary fibrosis patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18508830      PMCID: PMC3255086          DOI: 10.1183/09031936.00015808

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  30 in total

1.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

2.  DR beta 1 allelic distribution in the Spanish population.

Authors:  C Vilardell; F Isart; M Masó; M G Ercilla; J Martorell; A Gayà
Journal:  Transplant Proc       Date:  1995-08       Impact factor: 1.066

3.  Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: results of a 3 year follow-up.

Authors:  C Agustí; A Xaubet; A G Agustí; J Roca; J Ramirez; R Rodriguez-Roisin
Journal:  Eur Respir J       Date:  1994-04       Impact factor: 16.671

4.  Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases.

Authors:  U Specks; W J Martin; M S Rohrbach
Journal:  Am Rev Respir Dis       Date:  1990-01

Review 5.  Inherited interstitial lung disease.

Authors:  Christine Kim Garcia; Ganesh Raghu
Journal:  Clin Chest Med       Date:  2004-09       Impact factor: 2.878

6.  Complement receptor 1 gene polymorphisms are associated with idiopathic pulmonary fibrosis.

Authors:  Michele Zorzetto; Ilaria Ferrarotti; Rocco Trisolini; Luigi Lazzari Agli; Roberta Scabini; Monique Novo; Annalisa De Silvestri; Marco Patelli; Miryam Martinetti; MariaClara Cuccia; Venerino Poletti; Ernesto Pozzi; Maurizio Luisetti
Journal:  Am J Respir Crit Care Med       Date:  2003-05-28       Impact factor: 21.405

7.  Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis.

Authors:  Antoni Xaubet; Alejandra Marin-Arguedas; Sergio Lario; Julio Ancochea; Ferran Morell; Juan Ruiz-Manzano; Eulogio Rodriguez-Becerra; Jose M Rodriguez-Arias; Pablo Inigo; Sergi Sanz; Josep M Campistol; Joaquim Mullol; Cesar Picado
Journal:  Am J Respir Crit Care Med       Date:  2003-05-13       Impact factor: 21.405

8.  Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis.

Authors:  Moises Selman; Hung-Mo Lin; Martha Montaño; Audrey L Jenkins; Andrea Estrada; Zhenwu Lin; Guirong Wang; Susan L DiAngelo; Xiaoxuan Guo; Todd M Umstead; C Max Lang; Annie Pardo; David S Phelps; Joanna Floros
Journal:  Hum Genet       Date:  2003-09-06       Impact factor: 4.132

9.  Single-breath carbon monoxide diffusing capacity prediction equations from a Mediterranean population.

Authors:  J Roca; R Rodriguez-Roisin; E Cobo; F Burgos; J Perez; J L Clausen
Journal:  Am Rev Respir Dis       Date:  1990-04

10.  Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese.

Authors:  John B Dixon; Prithi S Bhathal; Julie R Jonsson; Andrew F Dixon; Elizabeth E Powell; Paul E O'Brien
Journal:  J Hepatol       Date:  2003-12       Impact factor: 25.083

View more
  13 in total

1.  The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension.

Authors:  Vinayak Shenoy; Anderson J Ferreira; Yanfei Qi; Rodrigo A Fraga-Silva; Carlos Díez-Freire; Autumn Dooies; Joo Yun Jun; Srinivas Sriramula; Nithya Mariappan; Dorna Pourang; Changaram S Venugopal; Joseph Francis; Timothy Reudelhuber; Robson A Santos; Jawaharlal M Patel; Mohan K Raizada; Michael J Katovich
Journal:  Am J Respir Crit Care Med       Date:  2010-06-25       Impact factor: 21.405

2.  Profibrosing effect of angiotensin converting enzyme inhibitors in human lung fibroblasts.

Authors:  Gabriela Díaz-Piña; Eduardo Montes; Marco Checa; Carina Becerril; Carolina García de Alba; Anita Vega; Ignacio Páramo; Rosa Ordoñez-Razo; Victor Ruiz
Journal:  Lung       Date:  2015-02-06       Impact factor: 2.584

3.  Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis.

Authors:  Norihiko Sakai; Andrew M Tager
Journal:  Biochim Biophys Acta       Date:  2013-03-14

4.  JunD and HIF-1alpha mediate transcriptional activation of angiotensinogen by TGF-beta1 in human lung fibroblasts.

Authors:  Amal Abdul-Hafez; Ruijie Shu; Bruce D Uhal
Journal:  FASEB J       Date:  2009-02-11       Impact factor: 5.191

5.  Angiotensinogen promoter polymorphisms predict low diffusing capacity in U.S. and Spanish IPF cohorts.

Authors:  My-Trang T Dang; Chenyang Gu; Jeannie I Klavanian; Katherine A Jernigan; Karen H Friderici; Yuehua Cui; Maria Molina-Molina; Julio Ancochea; Antoni Xaubet; Bruce D Uhal
Journal:  Lung       Date:  2013-05-30       Impact factor: 2.584

6.  Polymorphisms in thrombophilia and renin-angiotensin system pathways, preterm delivery, and evidence of placental hemorrhage.

Authors:  Julia Warner Gargano; Claudia B Holzman; Patricia K Senagore; M Lynne Reuss; Dorothy R Pathak; Karen H Friderici; Katherine Jernigan; Rachel Fisher
Journal:  Am J Obstet Gynecol       Date:  2009-09       Impact factor: 8.661

7.  Angiotensinogen gene transcription in pulmonary fibrosis.

Authors:  Bruce D Uhal; My-Trang T Dang; Xiaopeng Li; Amal Abdul-Hafez
Journal:  Int J Pept       Date:  2012-02-20

Review 8.  Genetic architecture of human fibrotic diseases: disease risk and disease progression.

Authors:  Agnès Gardet; Timothy S Zheng; Joanne L Viney
Journal:  Front Pharmacol       Date:  2013-12-18       Impact factor: 5.810

9.  Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression.

Authors:  Stylianos Bournazos; Jacob Grinfeld; Karen M Alexander; John T Murchison; William A Wallace; Pauline McFarlane; Nikhil Hirani; A John Simpson; Ian Dransfield; Simon P Hart
Journal:  BMC Pulm Med       Date:  2010-10-07       Impact factor: 3.317

10.  Fcγ receptor IIIb (CD16b) polymorphisms are associated with susceptibility to idiopathic pulmonary fibrosis.

Authors:  Stylianos Bournazos; Irini Bournazou; John T Murchison; William A Wallace; Pauline McFarlane; Nikhil Hirani; A John Simpson; Ian Dransfield; Simon P Hart
Journal:  Lung       Date:  2010-10-06       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.